TapImmune (TPIV) Stock Research, Analysis & News

Quick Analysis on TapImmune (TPIV) Stock as of December 12, 2017

The Stock pays no dividend
Average trading volume is relatively low at 0
(See more information about TapImmune (TPIV) Stock below)

TapImmune (TPIV) Stock Profile Summary

TapImmune Inc., a biotechnology company, engages in the discovery and development of immunotherapeutics for the treatment of cancer, infectious diseases, autoimmune disorders, and transplant tissue rejection. The company focuses on conducting studies using its transporters of antigen processing (TAP) gene technology in combination with an adeno virus. Its products include TAP cancer vaccine, which is under preclinical trial used for the treatment of breast cancer, prostate cancer, lung cancer, liver cancer, melanoma, renal cancer, and colorectal cancer. The company also develops therapeutics for infectious diseases using its TAP gene technology. TapImmune has strategic relationships with University of British Columbia, Crucell Holland B.V., Aeras Global TB Foundation, National Institute of Allergy and Infectious Diseases, and Mayo Clinic. The company was founded in 1999 and is based in Seattle, Washington.

TapImmune (TPIV) Stock Key Statistics Research and Analysis as of December 12, 2017

Latest Market News on TapImmune (TPIV)


Click here to find the latest news on TapImmune (TPIV)

Looking for Market Opportunties?


Today's Most Active Stocks
Today's Biggest Price % Gainers
Today's Biggest Price % Losers
Today's Unusual Rising Volume Stocks
Today's Unusual Falling Volume Stocks
Research Reports
Earning Calendar
ETF Center